Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
Open Access
- 28 November 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2729
Abstract
Cardiovascular disease (CVD) and ischemic stroke (IS) are the primary causes of mortality worldwide. Hypercholesterolemia has been recognized as an independent risk factor for CVD and IS. Numerous clinical trials have unequivocally demonstrated that reducing levels of low-density lipoprotein cholesterol (LDL-C) significantly mitigates the risk of both cardiac and cerebral vascular events, thereby enhancing patient prognosis. Consequently, LDL-C reduction remains a pivotal therapeutic strategy for CVD and IS. However, despite intensive statin therapy, a significant proportion of high-risk hypercholesterolemic patients fail to achieve sufficient reductions in LDL-C levels. In response to this challenge, an inhibitor targeting proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed as a therapeutic intervention for hyperlipidemia. Numerous randomized controlled trials (RCTs) have conclusively demonstrated that the combination of PCSK9 inhibitors and statins significantly enhances prognosis not only in patients with CVD, but also in those afflicted with symptomatic intracranial artery stenosis (sICAS). PCSK9 inhibitors significantly reduce LDL-C levels by binding to the PCSK9 molecule and preventing its interaction with LDLRs. This prevents degradation of the receptor and increases uptake of LDL-C, thereby decreasing its concentration in blood. Besides significantly reducing LDL-C levels, PCSK9 inhibitors also demonstrate anti-inflammatory and anti-atherosclerotic properties while promoting plaque stabilization and inhibiting platelet aggregation and thrombosis. This article aims to provide a comprehensive review based on the relevant literature regarding the evolving understanding of pleiotropic effects associated with PCSK9 inhibitors, particularly focusing on their impact on the cardiovascular system and central nervous system.Keywords
Funding Information
- National Science and Technology Innovation 2030–Major Program of Brain Science and Brain-Inspired Intelligence Research (2021ZD0201807, YKK23111, MJR202310040, MJR202410130, NMUB20220060, ZKX22031, SJCX24_0763)
- Nanjing Medical Science and Technology Development Foundation (2021ZD0201807, YKK23111, MJR202310040, MJR202410130, NMUB20220060, ZKX22031, SJCX24_0763)
- Medjaden Academy & Research Foundation for Young Scientists (2021ZD0201807, YKK23111, MJR202310040, MJR202410130, NMUB20220060, ZKX22031, SJCX24_0763)
- Nanjing Medical University Science and Technique Development Foundation Project (2021ZD0201807, YKK23111, MJR202310040, MJR202410130, NMUB20220060, ZKX22031, SJCX24_0763)
- Nanjing Medical Science and Technique Development Foundation Project (2021ZD0201807, YKK23111, MJR202310040, MJR202410130, NMUB20220060, ZKX22031, SJCX24_0763)
- Postgraduate Research & Practice Innovation Program of Jiangsu Province (2021ZD0201807, YKK23111, MJR202310040, MJR202410130, NMUB20220060, ZKX22031, SJCX24_0763)
This publication has 84 references indexed in Scilit:
- ApoBandNon‐HDLCholesterol VersusLDLCholesterol for Ischemic Stroke RiskAnnals of Neurology, 2022
- Lipoprotein(a) and its Significance in Cardiovascular DiseaseJAMA Cardiology, 2022
- A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9European Journal of Clinical Pharmacology, 2021
- Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumabThe International Journal of Cardiovascular Imaging, 2021
- The Knowns and Unknowns of Contemporary Statin Therapy for Familial HypercholesterolemiaCurrent Atherosclerosis Reports, 2020
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsJAMA, 2016
- Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)Diabetologia, 2015
- Local effects of human PCSK9 on the atherosclerotic lesionThe Journal of Pathology, 2015
- PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signalingCellular and Molecular Life Sciences, 2012
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathwayMolecular and Cellular Biochemistry, 2011